$KURA has experienced significant volatility following an announcement of a $330 million upfront payment and partnership. Despite the deal, the company's stock has declined, raising concerns among investors about its future potential. Analysts suggest that the recent price action may have mitigated the upside potential of key near-term catalysts. The company is currently under cash and has been described as operating in a bear market, even after announcing a pivotal asset, ziftomenib, which targets a billion-dollar market. In contrast, $KUT.V is set to be acquired by VRC Companies at $5 per share, representing a 22% premium to its last closing price and valuing the company at $95 million. This acquisition comes amid criticism of the board's decisions and the market's reaction to the deal.